GLP-1 Therapy: Nutrition Key for Indians' Success

Leading Indian endocrinologists have published a consensus emphasizing that GLP-1 therapies, such as semaglutide and tirzepatide, require robust nutritional support for optimal outcomes. These medications, while effective for weight and diabetes management, suppress appetite, potentially leading to nutrient deficiencies and muscle loss if not managed with a suitable diet. The protocol, detailed in Obesity Pillars, aims to address these challenges specifically for the Indian population.

Key concerns include gastrointestinal side effects, reduced intake of vital nutrients like vitamins D and B12, and significant loss of lean muscle mass, which can be exacerbated in individuals of Asian Indian descent. Experts recommend a personalized approach focusing on adequate protein intake (1.2-1.5 g/kg body weight during weight loss), quality carbohydrates, and healthy fats. Regular monitoring for micronutrient deficiencies and ensuring sufficient hydration are also critical components.

Furthermore, the consensus underscores the importance of exercise, particularly resistance training, in preserving muscle mass and improving long-term health. Maintaining weight loss after discontinuing GLP-1 therapy remains a significant challenge, with many patients regaining weight. Therefore, continued nutritional guidance and lifestyle support are deemed essential for sustained success beyond the medication's duration.